Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma <i>In Situ</i> Induces Synthetic Lethality and Chemoprevention

Reem Ali(Hamad bin Khalifa University), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Claire Seedhouse(University of Nottingham), Emad A. Rakha(Nottingham University Hospitals NHS Trust), Islam M. Miligy(University of Nottingham), Sameer Mirza(Nebraska Medical Center), Katia A. Mesquita(University of Nottingham), Andrew R. Green(Nottingham Biomedical Research Centre), Abdulbaqi Al-Kawaz(University of Nottingham), Vimla Band(Nebraska Medical Center), Michael S. Toss(Nottingham City Hospital)
Cancer Research
October 8, 2018
10.1158/0008-5472.can-18-0633
Cited by 31

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
|Nature Communications|2016|1.8k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374